Investment analysts at Wells Fargo & Company initiated coverage on shares of Metsera (NASDAQ:MTSR - Get Free Report) in a research report issued on Friday,Benzinga reports. The firm set an "overweight" rating and a $65.00 price target on the stock. Wells Fargo & Company's price objective would suggest a potential upside of 134.57% from the company's previous close.
A number of other research analysts also recently commented on the stock. Guggenheim lifted their price objective on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th. Evercore ISI began coverage on Metsera in a research report on Tuesday, February 25th. They set an "outperform" rating on the stock. Bank of America began coverage on Metsera in a research note on Tuesday, February 25th. They issued a "buy" rating and a $38.00 price objective on the stock. Finally, Cantor Fitzgerald initiated coverage on Metsera in a report on Tuesday, February 25th. They set an "overweight" rating on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Metsera currently has a consensus rating of "Buy" and an average price target of $55.00.
Read Our Latest Stock Report on Metsera
Metsera Price Performance
Shares of NASDAQ MTSR opened at $27.71 on Friday. The firm's fifty day moving average is $25.38. Metsera has a 52-week low of $12.30 and a 52-week high of $37.99.
Metsera (NASDAQ:MTSR - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($1.03) EPS for the quarter.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the company. Strs Ohio bought a new stake in Metsera in the 1st quarter valued at about $76,000. New York State Common Retirement Fund acquired a new stake in shares of Metsera in the first quarter valued at approximately $131,000. Corebridge Financial Inc. bought a new stake in shares of Metsera in the first quarter valued at approximately $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Metsera during the first quarter worth approximately $248,000. Finally, MetLife Investment Management LLC bought a new position in Metsera during the 1st quarter worth $254,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
